采用阿霉素-链脲佐菌素与5-氟尿嘧啶-达卡巴嗪交替联合方案治疗晚期甲状腺髓样癌。降钙素瘤研究组（GETC）。
Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
作者信息
Nocera M, Baudin E, Pellegriti G, Cailleux A F, Mechelany-Corone C, Schlumberger M
机构信息
Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institute Gustave-Roussy, Villejuif Cedex, 94805, France.
出版信息
Br J Cancer. 2000 Sep;83(6):715-8. doi: 10.1054/bjoc.2000.1314.
Abstract
Combinations of doxorubicin and streptozocin and 5-FU and dacarbazine were given alternately to 20 patients with metastatic medullary thyroid carcinoma. Three partial responses and 10 long-term stabilizations were observed. No unexpected toxicity occurred.
摘要
对20例转移性甲状腺髓样癌患者交替给予阿霉素与链脲霉素、5-氟尿嘧啶和达卡巴嗪联合治疗。观察到3例部分缓解和10例长期病情稳定。未发生意外毒性反应。
相似文献
1
Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
Br J Cancer. 2000 Sep;83(6):715-8. doi: 10.1054/bjoc.2000.1314.
2
Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
Br J Cancer. 1995 Feb;71(2):363-5. doi: 10.1038/bjc.1995.73.
3
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
J Clin Oncol. 2005 Aug 1;23(22):4897-904. doi: 10.1200/JCO.2005.03.616.
4
5
[Medullary thyroid carcinoma: evolution of concepts].
Arch Anat Cytol Pathol. 1998;46(1-2):100-11.
6
[Causes of death in patients with medullary cancer of the thyroid. GETC. Groupe d'Etude des Tumeurs à Calcitonine].
Presse Med. 1996 Nov 30;25(37):1819-22.
7
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
Ann Oncol. 1994 Oct;5(8):763-5. doi: 10.1093/oxfordjournals.annonc.a058984.
8
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.
J Clin Oncol. 2004 Dec 1;22(23):4762-71. doi: 10.1200/JCO.2004.04.024.
9
Novel treatment of medullary thyroid cancer.
Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):367-72. doi: 10.1097/MED.0b013e3283304f0c.
10
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Br J Cancer. 2000 Dec;83(12):1594-8. doi: 10.1054/bjoc.2000.1512.
引用本文的文献
1
Overview of management and therapeutic advances in medullary thyroid cancer.
Endocr Oncol. 2025 Mar 11;5(1):e240077. doi: 10.1530/EO-24-0077. eCollection 2025 Jan.
2
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Cell Commun Signal. 2024 Sep 28;22(1):460. doi: 10.1186/s12964-024-01837-x.
3
Psychosocial Characteristics and Experiences in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2) and Medullary Thyroid Carcinoma (MTC).
Children (Basel). 2022 May 25;9(6):774. doi: 10.3390/children9060774.
4
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Front Endocrinol (Lausanne). 2020 Aug 7;11:490. doi: 10.3389/fendo.2020.00490. eCollection 2020.
5
Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy.
Int J Mol Sci. 2020 Jul 13;21(14):4951. doi: 10.3390/ijms21144951.
6
New Treatment Options for Metastatic Thyroid Cancer.
Fed Pract. 2015 Aug;32(Suppl 7):21S-26S.
7
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Oncologist. 2019 Jan;24(1):16-e14. doi: 10.1634/theoncologist.2018-0452. Epub 2018 Oct 8.
8
Targeted Therapy for Medullary Thyroid Cancer: A Review.
Front Oncol. 2017 Oct 6;7:238. doi: 10.3389/fonc.2017.00238. eCollection 2017.
9
Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Endocr Pathol. 2016 Dec;27(4):312-324. doi: 10.1007/s12022-016-9449-0.
10
Management of hereditary medullary thyroid carcinoma.
Endocrine. 2016 Jul;53(1):7-17. doi: 10.1007/s12020-016-0873-1. Epub 2016 Feb 2.
本文引用的文献
1
Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia.
Surg Oncol Clin N Am. 1998 Oct;7(4):681-706.
2
Medullary thyroid cancer: the role of radiotherapy in local control.
Eur J Surg Oncol. 1996 Dec;22(6):588-91. doi: 10.1016/s0748-7983(96)92294-5.
3
Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control.
Thyroid. 1996 Aug;6(4):305-10. doi: 10.1089/thy.1996.6.305.
4
Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine.
Cancer. 1994 Jan 15;73(2):432-6. doi: 10.1002/1097-0142(19940115)73:2<432::aid-cncr2820730231>3.0.co;2-k.
5
The management of patients with advanced carcinoid tumors and islet cell carcinomas.
Ann Intern Med. 1994 Feb 15;120(4):302-9. doi: 10.7326/0003-4819-120-4-199402150-00008.
6
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
Ann Oncol. 1994 Oct;5(8):763-5. doi: 10.1093/oxfordjournals.annonc.a058984.
7
A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
Ann Oncol. 1995 Jan;6(1):77-9. doi: 10.1093/oxfordjournals.annonc.a059049.
8
Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
Br J Cancer. 1995 Feb;71(2):363-5. doi: 10.1038/bjc.1995.73.
9
Reporting results of cancer treatment.
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
10
Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients.
Medicine (Baltimore). 1984 Nov;63(6):319-42.
Zotero 插件